Atrial Fibrillation Recurrence Following Cardioversion: the Role of Clinical Factors and Alpha Defensin Levels

Hillel Yaffe Medical Center

Status: Unknown

Conditions: Atrial Fibrillation

Treatments: Procedure: Cardioversion; Drug: Colchicine Tablets

Study type: Interventional

Funder types: Other

Identifiers

NCT04155879

HYMC-19-0074

Details and patient eligibility

About

Atrial fibrillation and inflammation are strongly correlated. The aim of this study is to evaluate whether inflammation markers (alpha Defensin) predict maintenance of sinus rhythm following cardioversion. A secondary aim is to evaluate the role of Colchicine, an anti-inflammatory medication, in reducing the recurrence rate of atrial fibrillation.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Atrial fibrillation
• Candidate for cardioversion

Exclusion criteria

• Colchicine allergy
• Hepatic or renal failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

300 participants in 2 patient groups

Control Group

No Intervention group

Description:

Cardioversion without treatment with Colchicine

Treatment group

Active Comparator group

Description:

This arm will undergo cardioversion followed by Colchicine (0.5 mg 2x per day) for six months

Treatment:

Drug: Colchicine Tablets

Procedure: Cardioversion